Transdermal Delivery of Repaglinide from Solid Lipid Nanoparticles in Diabetic Rats: In Vitro and In Vivo Studies

Transdermal patches loaded with Solid Lipid Nanoparticles has been used as a suitable dosage to maintain the blood glucose level in diabetic patients. Repaglinide was taken as model antidiabetic drug get incorporated in Solid lipid Nanoparticles (SLNs) by a hot homogenization method using cephalin and lecithin as lipids and Tween 80 as stabilizer. The prepared nanoparticles evaluated for particle size measurement, poly dispersity index, Zeta potential, entrapment efficiency, and In vitroIn vivo release studies so as to ensure the quality Solid lipid Nanoparticles. Report of Scanning Electron Microscopy showed that the SLN particles were spherical shape and has size range between 85 – 120 nm, the poly dispersity indexes was found to be 0.148 to 0.227. The zeta potential range between 27.1 ± 2.5 to −36.1 ± 2.1 mV. The entrapment efficiency (EE %) and drug loading capacity (DL %) was 80.4 ± 4.2 % to 92.3 ± 7.2 % respectively. Repaglanide SLN was incorporated on transdermal patches and performed ex-in vivo release studies. Blood glucose level was calculated by using Diabetic rat, blood glucose levels of rats decreased and it could be sustained at such levels over 48 hrs. SLN loaded transdermal patches showed more suitable controlled release kinetics for protein delivery.